| Year |
Citation |
Score |
| 2016 |
Landowski TH, Guntle GP, Zhao D, Jagadish B, Mash EA, Dorr RT, Raghunand N. Magnetic Resonance Imaging Identifies Differential Response to Pro-Oxidant Chemotherapy in a Xenograft Model. Translational Oncology. 9: 228-35. PMID 27267841 DOI: 10.1016/J.Tranon.2016.04.007 |
0.342 |
|
| 2015 |
Samulitis BK, Pond KW, Pond E, Cress AE, Patel H, Wisner L, Patel C, Dorr RT, Landowski TH. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors. Cancer Biology & Therapy. 16: 43-51. PMID 25485960 DOI: 10.4161/15384047.2014.986967 |
0.394 |
|
| 2015 |
Samulitis Bk, Pond E, Pond K, Cress AE, Dorr RT, Landowski TH. Abstract B42: Adaptive drug resistance is associated with phenotypic reprogramming and hypersensitivity to HDAC inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-B42 |
0.385 |
|
| 2015 |
Remers WA, Iyengar BS, Dorr RT, Wisner L, Bates RB. Synthesis and antitumor activity of heterocycles related to carbendazim Journal of Heterocyclic Chemistry. 52: 136-141. DOI: 10.1002/Jhet.1976 |
0.368 |
|
| 2014 |
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, ... ... Dorr RT, et al. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 124: 1259-65. PMID 25016003 DOI: 10.1182/Blood-2014-04-570044 |
0.319 |
|
| 2013 |
Landowski TH, Samulitis BK, Dorr RT. The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investigational New Drugs. 31: 1616-25. PMID 24037082 DOI: 10.1007/S10637-013-0019-8 |
0.436 |
|
| 2013 |
Escalante AM, McGrath RT, Karolak MR, Dorr RT, Lynch RM, Landowski TH. Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. Cancer Chemotherapy and Pharmacology. 71: 1567-76. PMID 23572175 DOI: 10.1007/S00280-013-2156-3 |
0.362 |
|
| 2013 |
Dorr RT, Samulitis BK, Wisner L, Han H, Zhao Y, Beroza P, Damodaran K, Igarashi S, Landowski TH, Von Hoff DD. Characterization of a membrane-active anti-tumor agent, UA8967 Investigational New Drugs. 31: 576-586. PMID 23179338 DOI: 10.1007/S10637-012-9901-Z |
0.447 |
|
| 2013 |
Barr PM, Briehl MM, Bernstein SH, Friedberg JW, Baran A, Peterson DR, Persky DO, Casulo C, Herr MM, Littleton J, Cebula E, Schwartz M, Puvvada SD, Dorr RT, Fisher RI, et al. Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study Blood. 122: 89-89. DOI: 10.1182/Blood.V122.21.89.89 |
0.343 |
|
| 2012 |
Guntle GP, Jagadish B, Mash EA, Powis G, Dorr RT, Raghunand N. Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium. Translational Oncology. 5: 190-9. PMID 22741038 DOI: 10.1593/Tlo.11322 |
0.354 |
|
| 2012 |
Tome ME, Frye JB, Coyle DL, Jacobson EL, Samulitis BK, Dvorak K, Dorr RT, Briehl MM. Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. Experimental and Therapeutic Medicine. 3: 845-852. PMID 22529877 DOI: 10.3892/Etm.2012.487 |
0.324 |
|
| 2012 |
Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Molecular Cancer Research : McR. 10: 392-400. PMID 22275514 DOI: 10.1158/1541-7786.Mcr-11-0359 |
0.356 |
|
| 2012 |
Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA. Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423. Cancer Chemotherapy and Pharmacology. 69: 1039-49. PMID 22186884 DOI: 10.1007/S00280-011-1784-8 |
0.324 |
|
| 2012 |
Samulitis B, Wisner L, Dorr R, Landowski TH. Abstract 797: Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with characteristics of EMT Cancer Research. 72: 797-797. DOI: 10.1158/1538-7445.Am2012-797 |
0.388 |
|
| 2011 |
Roman NO, Samulitis BK, Wisner L, Landowski TH, Dorr RT. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemotherapy and Pharmacology. 67: 183-92. PMID 20339847 DOI: 10.1007/S00280-010-1306-0 |
0.784 |
|
| 2011 |
Dorr RT, Wisner L, Samulitis B, Landowski TH, Remers WA. Abstract 671: Tumor delay and mechanism of action studies of a novel cyanoaziridine derivative, AMP423 Cancer Research. 71: 671-671. DOI: 10.1158/1538-7445.Am2011-671 |
0.472 |
|
| 2010 |
Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma. Cancer. 116: 3683-91. PMID 20564083 DOI: 10.1002/Cncr.25119 |
0.401 |
|
| 2010 |
Cohen SJ, Zalupski MM, Modiano MR, Conkling P, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66: 287-94. PMID 19855966 DOI: 10.1007/S00280-009-1162-Y |
0.372 |
|
| 2010 |
Moulder S, Dhillon N, Ng C, Hong D, Wheler J, Naing A, Tse S, La Paglia A, Dorr R, Hersh E, Boytim M, Kurzrock R. A phase i trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer Investigational New Drugs. 28: 634-640. PMID 19499186 DOI: 10.1007/S10637-009-9273-1 |
0.345 |
|
| 2009 |
Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT. Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer. The Journal of Pharmacology and Experimental Therapeutics. 331: 636-47. PMID 19657049 DOI: 10.1124/Jpet.109.156406 |
0.802 |
|
| 2009 |
Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT. Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorganic & Medicinal Chemistry Letters. 19: 4752-5. PMID 19615898 DOI: 10.1016/J.Bmcl.2009.06.063 |
0.764 |
|
| 2009 |
Henderson MC, Shaw YJ, Wang H, Han H, Hurley LH, Flynn G, Dorr RT, Von Hoff DD. UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Molecular Cancer Therapeutics. 8: 36-44. PMID 19139111 DOI: 10.1158/1535-7163.Mct-08-0789 |
0.768 |
|
| 2009 |
Samulitis BK, Landowski TH, Dorr RT. Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Investigational New Drugs. 27: 89-98. PMID 18607542 DOI: 10.1007/S10637-008-9149-9 |
0.307 |
|
| 2008 |
Moulder SL, Dhillon N, Hong DS, Ng CS, Camacho LH, Hersh EM, Grenier KA, Boytim ML, Dorr RT, Kurzrock R. A phase I study of imexon in combination with docetaxel (DOC) for the treatment of patients with breast, lung and prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3589. PMID 27949687 DOI: 10.1200/Jco.2008.26.15_Suppl.3589 |
0.346 |
|
| 2008 |
Cohen SJ, Zalupski MM, Modiano MR, Conkling PR, Patt YZ, Davis P, Dorr RT, Boytim ML, Hersh EM. A phase I study of imexon inj plus gemcitabine as first-line therapy for advanced pancreatic cancer with preclinical mechanistic study of dose limiting toxicity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4619. PMID 27948476 DOI: 10.1200/Jco.2008.26.15_Suppl.4619 |
0.393 |
|
| 2008 |
Stratton SP, Saboda KL, Myrdal PB, Gupta A, McKenzie NE, Brooks C, Salasche SJ, Warneke JA, Ranger-Moore J, Bozzo PD, Blanchard J, Einspahr JG, Dorr RT, Levine N, Alberts DS. Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutrition and Cancer. 60: 325-30. PMID 18444166 DOI: 10.1080/01635580701840391 |
0.328 |
|
| 2008 |
Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochemical Pharmacology. 75: 883-90. PMID 18062937 DOI: 10.1016/J.Bcp.2007.10.026 |
0.782 |
|
| 2008 |
Samlowski WE, Weber JS, Gonzalez R, Ribas A, O’Day SJ, Stephenson JJ, Sato T, Dorr RT, Grenier KA, Hersh EM. Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma Journal of Clinical Oncology. 26: 9066-9066. DOI: 10.1200/Jco.2008.26.15_Suppl.9066 |
0.364 |
|
| 2008 |
Landowski TH, Escalante AM, Jefferson A, Dorr RT, Lynch R. Inhibition of Autophagy Promotes Bortezomib-Mediated Cell Death in Myeloma Cells Blood. 112: 3677-3677. DOI: 10.1182/Blood.V112.11.3677.3677 |
0.363 |
|
| 2007 |
Piao WH, Wong R, Bai XF, Huang J, Campagnolo DI, Dorr RT, Vollmer TL, Shi FD. Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 179: 7415-23. PMID 18025185 DOI: 10.4049/Jimmunol.179.11.7415 |
0.333 |
|
| 2007 |
Baker AF, Landowski T, Dorr R, Tate WR, Gard JM, Tavenner BE, Dragovich T, Coon A, Powis G. The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3388-94. PMID 17545547 DOI: 10.1158/1078-0432.Ccr-06-0873 |
0.337 |
|
| 2007 |
Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow H-S, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R. Phase I Trial of Imexon in Patients With Advanced Malignancy Journal of Clinical Oncology. 25: 1779-1784. PMID 17470869 DOI: 10.1200/Jco.2006.08.9672 |
0.361 |
|
| 2007 |
Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 1109-17. PMID 17351106 DOI: 10.1124/Jpet.106.117457 |
0.8 |
|
| 2007 |
Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemotherapy and Pharmacology. 59: 749-57. PMID 17333195 DOI: 10.1007/S00280-006-0329-Z |
0.405 |
|
| 2007 |
Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Investigational New Drugs. 25: 107-14. PMID 17024575 DOI: 10.1007/S10637-006-9015-6 |
0.77 |
|
| 2007 |
Cohen SJ, Zalupski M, Modiano M, Conkling P, Mahadevan D, Wong L, Smith D, Dorr RT, Boytim M, Hersh EM. Phase I trial of imexon, Inj. plus gemcitabine in patients with advanced previously untreated pancreatic adenocarcinoma Journal of Clinical Oncology. 25: 15058-15058. DOI: 10.1200/Jco.2007.25.18_Suppl.15058 |
0.381 |
|
| 2006 |
Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-Cancer Drugs. 17: 1179-84. PMID 17075317 DOI: 10.1097/01.Cad.0000236305.43209.F0 |
0.777 |
|
| 2006 |
Tome ME, Johnson DB, Samulitis BK, Dorr RT, Briehl MM. Glucose 6-phosphate dehydrogenase overexpression models glucose deprivation and sensitizes lymphoma cells to apoptosis. Antioxidants & Redox Signaling. 8: 1315-27. PMID 16910779 DOI: 10.1089/Ars.2006.8.1315 |
0.353 |
|
| 2006 |
Samulitis BK, Landowski TH, Dorr RT. Correlates of imexon sensitivity in human multiple myeloma cell lines. Leukemia & Lymphoma. 47: 97-109. PMID 16321833 DOI: 10.1080/10428190500266210 |
0.411 |
|
| 2006 |
Thompson MA, Pham LV, Yoshimura L, Baker AF, Hersh EM, Dorr RT, Ford RJ. Redox Proteins GSTs A1, M1, O1, O2, P1; Prx-3, and Trx-1 Association with In Vitro Imexon Sensitivity in Multiple Myeloma Cell Lines. Blood. 108: 5077-5077. DOI: 10.1182/Blood.V108.11.5077.5077 |
0.386 |
|
| 2005 |
Dragovich T, Mendelson D, Gordon M, Long K, Downhour M, Dorr R, Hersh E. Phase I trial of imexon (IMX) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3153. PMID 27946194 DOI: 10.1200/Jco.2005.23.16_Suppl.3153 |
0.347 |
|
| 2005 |
Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S. Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines. International Journal of Gastrointestinal Cancer. 36: 15-28. PMID 16227632 DOI: 10.1385/Ijgc:36:1:015 |
0.807 |
|
| 2005 |
Chvapil M, Dorr RT. Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. Anti-Cancer Drugs. 16: 757-762. PMID 16027526 DOI: 10.1097/01.Cad.0000171767.59187.C2 |
0.322 |
|
| 2005 |
Landowski TH, Megli CJ, Nullmeyer KD, Lynch RM, Dorr RT. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Research. 65: 3828-36. PMID 15867381 DOI: 10.1158/0008-5472.Can-04-3684 |
0.383 |
|
| 2005 |
Lambert JD, Sang S, Dougherty A, Caldwell CG, Meyers RO, Dorr RT, Timmermann BN. Cytotoxic lignans from Larrea tridentata. Phytochemistry. 66: 811-5. PMID 15797607 DOI: 10.1016/J.Phytochem.2005.02.007 |
0.788 |
|
| 2004 |
Dorr RT, Dragovich T, Hersh E, Patrick K. Phase I clinical trial of imexon: A mitochondrial thiol oxidant. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3181. PMID 28014914 DOI: 10.1200/Jco.2004.22.14_Suppl.3181 |
0.382 |
|
| 2004 |
Iyengar BS, Dorr RT, Remers WA. Chemical basis for the biological activity of imexon and related cyanoaziridines. Journal of Medicinal Chemistry. 47: 218-23. PMID 14695835 DOI: 10.1021/Jm030225V |
0.316 |
|
| 2004 |
Lambert J, Dorr R, Timmermann B. Nordihydroguaiaretic Acid: A Review of Its Numerous and Varied Biological Activities Pharmaceutical Biology. 42: 149-158. DOI: 10.1080/13880200490512016 |
0.301 |
|
| 2003 |
Hehn ST, Dorr RT, Miller TP. Mood alterations in patients treated with chlorambucil. Clinical Lymphoma. 4: 179-82. PMID 14715101 DOI: 10.3816/Clm.2003.N.028 |
0.301 |
|
| 2002 |
Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, Coon A, Dorr RT. Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells. Molecular Cancer Therapeutics. 1: 185-95. PMID 12467213 |
0.672 |
|
| 2002 |
Lambert JD, Zhao D, Meyers RO, Kuester RK, Timmermann BN, Dorr RT. Nordihydroguaiaretic acid: hepatotoxicity and detoxification in the mouse. Toxicon : Official Journal of the International Society On Toxinology. 40: 1701-8. PMID 12457882 DOI: 10.1016/S0041-0101(02)00203-9 |
0.78 |
|
| 2002 |
Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT. Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells. Anti-Cancer Drugs. 13: 1031-42. PMID 12439337 DOI: 10.1097/00001813-200211000-00007 |
0.69 |
|
| 2001 |
Skibo EB, Xing C, Dorr RT. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. Journal of Medicinal Chemistry. 44: 3545-62. PMID 11606119 DOI: 10.1021/Jm010085U |
0.409 |
|
| 2001 |
Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treatment Reviews. 27: 221-33. PMID 11545542 DOI: 10.1053/Ctrv.2001.0228 |
0.303 |
|
| 2001 |
Waltmire CN, Alberts DS, Dorr RT. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. Anti-Cancer Drugs. 12: 595-602. PMID 11487716 DOI: 10.1097/00001813-200108000-00006 |
0.42 |
|
| 2001 |
Lambert JD, Meyers RO, Timmermann BN, Dorr RT. tetra-O-methylnordihydroguaiaretic acid inhibits melanoma in vivo. Cancer Letters. 171: 47-56. PMID 11485827 DOI: 10.1016/S0304-3835(01)00560-2 |
0.79 |
|
| 2001 |
Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood. 97: 3544-51. PMID 11369649 DOI: 10.1182/Blood.V97.11.3544 |
0.703 |
|
| 2001 |
Lambert JD, Meyers RO, Timmermann BN, Dorr RT. Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse. Journal of Chromatography. B, Biomedical Sciences and Applications. 754: 85-90. PMID 11318430 DOI: 10.1016/S0378-4347(00)00592-2 |
0.783 |
|
| 2001 |
Dorr RT, Liddil JD, Sami SM, Remers W, Hersh EM, Alberts DS. Preclinical antitumor activity of the azonafide series of anthracene-based DNA intercalators. Anti-Cancer Drugs. 12: 213-20. PMID 11290869 DOI: 10.1097/00001813-200103000-00007 |
0.435 |
|
| 2001 |
Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 47: 83-8. PMID 11221967 DOI: 10.1007/S002800000207 |
0.332 |
|
| 2000 |
Lopez AM, Ketchum M, Nichols H, Xu MJ, Peng YM, Dorr RT, Alberts DS. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies Cancer Chemotherapy and Pharmacology. 46: 411-415. PMID 11127946 DOI: 10.1007/S002800000154 |
0.361 |
|
| 2000 |
Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochemistry and Photobiology. 72: 526-32. PMID 11045725 DOI: 10.1562/0031-8655(2000)072<0526:Ieeati>2.0.Co;2 |
0.666 |
|
| 2000 |
Sami SM, Dorr RT, Alberts DS, Sólyom AM, Remers WA. Analogues of amonafide and azonafide with novel ring systems. Journal of Medicinal Chemistry. 43: 3067-73. PMID 10956214 DOI: 10.1021/Jm9905817 |
0.342 |
|
| 2000 |
Stratton SP, Bangert JL, Alberts DS, Dorr RT. Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice. Cancer Letters. 158: 47-52. PMID 10940508 DOI: 10.1016/S0304-3835(00)00498-5 |
0.318 |
|
| 2000 |
Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochemical Pharmacology. 60: 749-58. PMID 10930529 DOI: 10.1016/S0006-2952(00)00380-4 |
0.709 |
|
| 2000 |
Bhardwaj R, Hadley ME, Dorr RT, Dvorakova K, Brooks C, Blanchard J. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I. Pharmaceutical Research. 17: 593-9. PMID 10888312 DOI: 10.1023/A:1007525117894 |
0.64 |
|
| 2000 |
Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. European Journal of Cancer (Oxford, England : 1990). 36: 1292-7. PMID 10882869 DOI: 10.1016/S0959-8049(00)00108-8 |
0.356 |
|
| 2000 |
Xing C, Wu P, Skibo EB, Dorr RT. Design of cancer-specific antitumor agents based on aziridinylcyclopent[b]indoloquinones. Journal of Medicinal Chemistry. 43: 457-66. PMID 10669573 DOI: 10.1021/Jm990466W |
0.383 |
|
| 1999 |
Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemotherapy and Pharmacology. 44: 303-306. PMID 10447577 DOI: 10.1007/S002800050981 |
0.386 |
|
| 1999 |
Mayr CA, Sami SM, Remers WA, Dorr RT. Intracellular localization of 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h]isoquino line-1,3-diones (azonafides) is not the limiting factor for their cytotoxicity: an in vitro confocal microscopy study. Anti-Cancer Drugs. 10: 163-70. PMID 10211546 DOI: 10.1097/00001813-199902000-00004 |
0.312 |
|
| 1999 |
Dvorakova K, Dorr RT, Valcic S, Timmermann B, Alberts DS. Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin. Cancer Chemotherapy and Pharmacology. 43: 331-5. PMID 10071985 DOI: 10.1007/S002800050903 |
0.681 |
|
| 1999 |
Iyengar BS, Dorr RT, Alberts DS, Hersh EM, Salmon SE, Remers WA. Novel antitumor 2-cyanoaziridine-1-carboxamides. Journal of Medicinal Chemistry. 42: 510-4. PMID 9986721 DOI: 10.1021/Jm980600X |
0.365 |
|
| 1999 |
Levine N, Dorr R, Ertl G, Brooks C, Alberts D. Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study Journal of Dermatological Treatment. 10: 127-132. DOI: 10.3109/09546639909056014 |
0.305 |
|
| 1998 |
Dorr RT, Meyers R, Snead K, Liddil JD. Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin. Cancer Chemotherapy and Pharmacology. 42: 149-54. PMID 9654115 DOI: 10.1007/S002800050798 |
0.802 |
|
| 1998 |
Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-Cancer Drugs. 9: 135-40. PMID 9510499 DOI: 10.1097/00001813-199802000-00004 |
0.345 |
|
| 1998 |
Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Dorr R, Dvorakova K, Salmon S, Harrison S, Worzalla J. Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. Cancer Chemotherapy and Pharmacology. 41: 22-8. PMID 9443610 DOI: 10.1007/S002800050703 |
0.65 |
|
| 1998 |
Alberts DS, Dorr RT. New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors. Oncologist. 3: 15-34. DOI: 10.1634/Theoncologist.3-1-15 |
0.378 |
|
| 1997 |
Iyengar BS, Dorr RT, Alberts DS, Sólyom AM, Krutzsch M, Remers WA. 1,4-disubstituted anthracene antitumor agents. Journal of Medicinal Chemistry. 40: 3734-8. PMID 9371238 DOI: 10.1021/Jm970308+ |
0.427 |
|
| 1997 |
Dvorakova K, Dorr RT, Gallegos A, McClure T, Powis G. Pharmacokinetic studies of the herbicide and antitumor compound oryzalin in mice. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 275-81. PMID 9323548 DOI: 10.1016/S0378-4347(97)00261-2 |
0.699 |
|
| 1997 |
Paine-Murrieta GD, Taylor CW, Curtis RA, Lopez MH, Dorr RT, Johnson CS, Funk CY, Thompson F, Hersh EM. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemotherapy and Pharmacology. 40: 209-14. PMID 9219503 DOI: 10.1007/S002800050648 |
0.404 |
|
| 1997 |
Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Research and Treatment. 42: 7-14. PMID 9116320 DOI: 10.1023/A:1005716214718 |
0.339 |
|
| 1997 |
Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharmaceutics & Drug Disposition. 18: 259-69. PMID 9113347 DOI: 10.1002/(Sici)1099-081X(199704)18:3<259::Aid-Bdd20>3.0.Co;2-X |
0.343 |
|
| 1997 |
Mayr CA, Sami SM, Dorr RT. In vitro cytotoxicity and DNA damage production in Chinese hamster ovary cells and topoisomerase II inhibition by 2-[2'-(dimethylamino)ethyl]-1, 2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones with substitutions at the 6 and 7 positions (azonafides). Anti-Cancer Drugs. 8: 245-56. PMID 9095329 DOI: 10.1097/00001813-199703000-00005 |
0.348 |
|
| 1997 |
Dorr RT, Lagel K, McLean S. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. European Journal of Cancer (Oxford, England : 1990). S21-5. PMID 8976818 DOI: 10.1016/S0959-8049(96)00314-0 |
0.361 |
|
| 1997 |
Sami SM, Dorr RT, Alberts DS, Sólyom AM, Remers WA. 2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships. Journal of Medicinal Chemistry. 39: 4978-87. PMID 8960558 DOI: 10.1021/Jm960623G |
0.397 |
|
| 1997 |
Gensler HL, Timmermann BN, Valcic S, Wächter GA, Dorr R, Dvorakova K, Alberts DS. Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green tea. Nutrition and Cancer. 26: 325-35. PMID 8910914 DOI: 10.1080/01635589609514488 |
0.694 |
|
| 1997 |
Dorr RT. Clinical pharmacology of taxanes as radiosensitizers and the thiol-based radioprotectant amifostine Seminars in Radiation Oncology. 7: 66-76. DOI: 10.1016/S1053-4296(97)80061-6 |
0.381 |
|
| 1996 |
Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Investigational New Drugs. 14: 131-7. PMID 8913833 DOI: 10.1007/Bf00210783 |
0.702 |
|
| 1996 |
Sami SM, Dorr RT, Sòlyom AM, Alberts DS, Iyengar BS, Remers WA. 6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships. Journal of Medicinal Chemistry. 39: 1609-18. PMID 8648600 DOI: 10.1021/Jm950742G |
0.428 |
|
| 1996 |
Dorr RT, Snead K, Liddil JD. Skin ulceration potential of paclitaxel in a mouse skin model in vivo. Cancer. 78: 152-6. PMID 8646711 DOI: 10.1002/(Sici)1097-0142(19970701)79:11<2266::Aid-Cncr30>3.0.Co;2-R |
0.336 |
|
| 1996 |
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 58: 1777-84. PMID 8637402 DOI: 10.1016/0024-3205(96)00160-9 |
0.309 |
|
| 1996 |
Dorr RT, Liddil JD, Klein MK, Hersh EM. Preclinical pharmacokinetics and antitumor activity of imexon. Investigational New Drugs. 13: 113-6. PMID 8617572 DOI: 10.1007/Bf00872858 |
0.433 |
|
| 1995 |
Sami SM, Dorr RT, Sólyom AM, Alberts DS, Remers WA. Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship. Journal of Medicinal Chemistry. 38: 983-93. PMID 7699715 DOI: 10.1021/Jm00006A018 |
0.354 |
|
| 1995 |
Dorr R, McLean S, Alberts D, Speicher L, Capizzi R. 579 Selective cardioprotection of rat heart myocytes exposed to DNA intercalating agents using amifostine (Ami) and its dephosphorylated metabolite, WR-1065 European Journal of Cancer. 31: S123. DOI: 10.1016/0959-8049(95)95833-R |
0.384 |
|
| 1994 |
Dorr RT, Lagel K. Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro. Chemico-Biological Interactions. 93: 117-28. PMID 8082231 DOI: 10.1016/0009-2797(94)90091-4 |
0.329 |
|
| 1993 |
Sami SM, Dorr RT, Alberts DS, Remers WA. 2-substituted 1,2-dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A new class of antitumor agent. Journal of Medicinal Chemistry. 36: 765-70. PMID 8459403 DOI: 10.1021/Jm00058A014 |
0.399 |
|
| 1993 |
List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1652-60. PMID 8102639 DOI: 10.1200/Jco.1993.11.9.1652 |
0.306 |
|
| 1993 |
Adel AL, Dorr RT, Liddil JD. The effect of anticancer drug sequence in experimental combination chemotherapy. Cancer Investigation. 11: 15-24. PMID 7678539 DOI: 10.3109/07357909309020256 |
0.347 |
|
| 1993 |
Dorr RT, Shipp NG, Liddil JD, Iyengar BS, Kunz KR, Remers WA. Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro. Cancer Chemotherapy and Pharmacology. 31: 1-5. PMID 1458553 DOI: 10.1007/Bf00695986 |
0.389 |
|
| 1992 |
Alberts DS, Dorr RT, Wunz TP, Remers WA, Einspahr J, Liu R, Salmon SE. In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs. Anti-Cancer Drugs. 2: 69-77. PMID 1958855 DOI: 10.1097/00001813-199102000-00010 |
0.4 |
|
| 1992 |
Dorr RT, Shipp NG, Lee KM. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro. Anti-Cancer Drugs. 2: 27-33. PMID 1958848 DOI: 10.1097/00001813-199102000-00003 |
0.381 |
|
| 1992 |
Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. Journal of the National Cancer Institute. 84: 1238-44. PMID 1640482 DOI: 10.1093/Jnci/84.16.1238 |
0.398 |
|
| 1992 |
Dorr RT. Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Seminars in Oncology. 19: 3-8. DOI: 10.5555/Uri:Pii:009377549290252V |
0.362 |
|
| 1991 |
Elam EA, Dorr RT, Lagel KE, Pond GD. Cutaneous ulceration due to contrast extravasation. Experimental assessment of injury and potential antidotes. Investigative Radiology. 26: 13-6. PMID 2022447 DOI: 10.1097/00004424-199101000-00003 |
0.318 |
|
| 1991 |
Islam I, Skibo EB, Dorr RT, Alberts DS. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. Journal of Medicinal Chemistry. 34: 2954-61. PMID 1920349 DOI: 10.1021/Jm00114A003 |
0.359 |
|
| 1991 |
Kunz KR, Iyengar BS, Dorr RT, Alberts DS, Remers WA. Structure-activity relationships for mitomycin C and mitomycin A analogues. Journal of Medicinal Chemistry. 34: 2281-6. PMID 1906109 DOI: 10.1021/Jm00111A051 |
0.381 |
|
| 1991 |
Iyengar BS, Dorr RT, Remers WA. Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia. Journal of Medicinal Chemistry. 34: 1947-51. PMID 1906107 DOI: 10.1021/Jm00111A004 |
0.319 |
|
| 1991 |
Alberts DS, Mason-liddil N, Plezia PM, Roe DJ, Dorr RT, Struck RF, Phillips JG. Lack of ranitidine effects on cyclophosphamide bon marrow toxicity or metabolism: A placebo-controlled clinical trial Journal of the National Cancer Institute. 83: 1739-1743. PMID 1770553 DOI: 10.1093/Jnci/83.23.1739 |
0.349 |
|
| 1991 |
Dorr RT, Liddil JD. Modulation of mitomycin C-induced multidrug resistance in vitro. Cancer Chemotherapy and Pharmacology. 27: 290-4. PMID 1671830 DOI: 10.1007/Bf00685114 |
0.377 |
|
| 1991 |
Dorr RT. Chemoprotectants for cancer chemotherapy. Seminars in Oncology. 18: 48-58. DOI: 10.5555/Uri:Pii:009377549190073V |
0.389 |
|
| 1990 |
Dorr RT, Lagel K. Interaction between cisplatin and mesna in mice. Journal of Cancer Research and Clinical Oncology. 115: 604-5. PMID 2514188 DOI: 10.1007/Bf00391367 |
0.359 |
|
| 1990 |
Dorr RT. Antidotes to vesicant chemotherapy extravasations. Blood Reviews. 4: 41-60. PMID 2182147 DOI: 10.1016/0268-960X(90)90015-K |
0.31 |
|
| 1989 |
Dorr RT, Salmon SE, Robertone A, Bonnem E. Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days. Journal of Interferon Research. 8: 717-25. PMID 3230330 DOI: 10.1089/Jir.1988.8.717 |
0.359 |
|
| 1989 |
Bellamy WT, Dalton WS, Meltzer P, Dorr RT. Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochemical Pharmacology. 38: 787-93. PMID 2930579 DOI: 10.1016/0006-2952(89)90232-3 |
0.361 |
|
| 1989 |
Dorr RT, Dawson BV, al-Obeidi F, Hadley ME, Levine N, Hruby VJ. Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. Investigational New Drugs. 6: 251-8. PMID 2852652 DOI: 10.1007/Bf00173642 |
0.316 |
|
| 1989 |
Dorr RT, Shipp NG. Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro. Immunopharmacology. 18: 31-8. PMID 2670822 DOI: 10.1016/0162-3109(89)90028-3 |
0.308 |
|
| 1989 |
Dorr RT, Soble MJ. H2-antagonists and carmustine. Journal of Cancer Research and Clinical Oncology. 115: 41-6. PMID 2564000 DOI: 10.1007/Bf00391598 |
0.37 |
|
| 1988 |
Liddil JD, Dorr RT. Schedule-dependent toxicity of tumor necrosis factor in rodents. Cancer Drug Delivery. 4: 159-67. PMID 3450380 DOI: 10.1089/Cdd.1987.4.159 |
0.301 |
|
| 1988 |
Iyengar BS, Dorr RT, Remers WA, Kowal CD. Nucleotide derivatives of 2,7-diaminomitosene. Journal of Medicinal Chemistry. 31: 1579-85. PMID 3397995 DOI: 10.1021/Jm00403A016 |
0.317 |
|
| 1988 |
Dorr RT, Soble MJ. Cimetidine enhances cisplatin toxicity in mice. Journal of Cancer Research and Clinical Oncology. 114: 1-2. PMID 3350834 DOI: 10.1007/Bf00390477 |
0.317 |
|
| 1988 |
Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Cancer Chemotherapy and Pharmacology. 22: 299-302. PMID 3168143 DOI: 10.1007/Bf00254235 |
0.307 |
|
| 1987 |
Soble MJ, Dorr RT, Plezia P, Breckenridge S. Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. Cancer Chemotherapy and Pharmacology. 20: 33-6. PMID 3621451 DOI: 10.1007/Bf00252956 |
0.325 |
|
| 1987 |
Dorr RT, Liddil JD, Soble MJ. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Investigational New Drugs. 4: 305-13. PMID 3583642 DOI: 10.1007/Bf00173503 |
0.449 |
|
| 1987 |
Dorr RT. Reduced thiol content in L1210 cells treated with BSO increases DNA crosslinking by melphalan. Biochemical and Biophysical Research Communications. 144: 47-52. PMID 3579919 DOI: 10.1016/S0006-291X(87)80473-4 |
0.311 |
|
| 1987 |
Dorr RT, Liddil JD, Trent JM, Dalton WS. Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochemical Pharmacology. 36: 3115-20. PMID 3117061 DOI: 10.1016/0006-2952(87)90620-4 |
0.354 |
|
| 1987 |
Wunz TP, Dorr RT, Alberts DS, Tunget CL, Einspahr J, Milton S, Remers WA. New antitumor agents containing the anthracene nucleus. Journal of Medicinal Chemistry. 30: 1313-21. PMID 2441053 DOI: 10.1021/Jm00391A009 |
0.422 |
|
| 1986 |
Dorr RT, Alberts DS, Soble M. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Cancer Chemotherapy and Pharmacology. 16: 91-4. PMID 3948308 DOI: 10.1007/Bf00256155 |
0.365 |
|
| 1986 |
Dorr RT, Soble MJ, Liddil JD, Keller JH. Mitomycin C skin toxicity studies in mice: reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 4: 1399-404. PMID 3091779 DOI: 10.1200/Jco.1986.4.9.1399 |
0.33 |
|
| 1985 |
Dorr RT, Peng YM, Alberts DS. Bisantrene solubility and skin toxicity studies: efficacy of sodium bicarbonate as a local ulceration antidote. Investigational New Drugs. 2: 351-7. PMID 6096286 DOI: 10.1007/Bf00171585 |
0.343 |
|
| 1985 |
Dorr RT, Alberts DS. Vinca Alkaloid Skin Toxicity: Antidote and Drug Disposition Studies in the Mouse Journal of the National Cancer Institute. 74: 113-120. DOI: 10.1093/Jnci/74.1.113 |
0.307 |
|
| 1984 |
Dorr RT, Alberts DS. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Investigational New Drugs. 1: 151-9. PMID 6678864 DOI: 10.1007/Bf00172074 |
0.396 |
|
| 1983 |
Meyskens FL, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit EA. A Phase I Trial of β-all-trans-Retinoic Acid Delivered via a Collagen Sponge and a Cervical Cap for Mild or Moderate Intraepithelial Cervical Neoplasia Journal of the National Cancer Institute. 71: 921-925. DOI: 10.1093/Jnci/71.5.921 |
0.305 |
|
| 1982 |
Appelbaum SJ, Mayersohn M, Dorr RT, Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemotherapy and Pharmacology. 8: 93-8. PMID 7094203 DOI: 10.1007/Bf00292878 |
0.31 |
|
| 1982 |
Dorr RT, Alberts DS. Cimetidine enhancement of cyclophosphamide antitumour activity. British Journal of Cancer. 45: 35-43. PMID 7059463 DOI: 10.1038/Bjc.1982.5 |
0.323 |
|
| 1982 |
Surwit EA, Graham V, Droegemueller W, Alberts D, Chvapil M, Dorr RT, Davis JR, Meyskens FL. Evaluation of topically applied trans-retinoic acid in the treatment of cervical intraepithelial lesions. American Journal of Obstetrics and Gynecology. 143: 821-3. PMID 7048932 DOI: 10.1016/0002-9378(82)90016-3 |
0.306 |
|
| 1981 |
Dorr RT, Alberts DS, Chen HS. The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. Cancer Chemotherapy and Pharmacology. 5: 17-20. PMID 7460191 DOI: 10.1007/Bf00578557 |
0.317 |
|
| 1981 |
Dorr RT, Alberts DS, Chen HS. Experimental model of doxorubicin extravasation in the mouse. Journal of Pharmacological Methods. 4: 237-50. PMID 7442269 DOI: 10.1016/0160-5402(80)90016-9 |
0.328 |
|
| 1981 |
Miller TP, Jones SE, Chester AB, Dorr RT. Phase II trial of vindesine in breast cancer, lymphoma and other tumors: future directions. Cancer Treatment Reviews. 81-6. PMID 7438127 DOI: 10.1016/S0305-7372(80)80013-2 |
0.309 |
|
| 1979 |
Dorr RT, Jones SE. Inapparent infiltrations associated with vindesine administration Medical and Pediatric Oncology. 6: 285-288. PMID 481319 DOI: 10.1002/Mpo.2950060403 |
0.365 |
|
| Show low-probability matches. |